Business
Endonovo Therapeutics Hires Nevena Zubcevik of Harvard Medical School as Chief Medical Officer
Endonovo Therapeutics Hires Nevena Zubcevik of Harvard Medical School as Chief Medical Officer.
About this update from Endonovo Therapeutics, Inc.
[{"type":"text","content":"\nLos Angeles, CA, May 02, 2019 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV), today announced the appointment of Nevena Zubcevik, DO, MSPT, ATC as its chief medical officer starting July 1, 2019.\n In her new role, Dr. Zubcevik will be in charge of medical and clinical strategy, including development and regulatory matters and new business development. That role will be increasingly important as Endonovo continues to develop its PEMF assets and the national roll-out of SofPulse. Dr. Zubcevik has over 24 years experience in the medical field, 17 of which are in clinical development, and is a licensed physician and educator. Prior to Endonovo, Dr. Zubcevik was an Attending Physician at Harvard Medical School/Partners HealthCare in the Physical Medicine and Rehabilitation Department. During her tenure at Harvard, Dr. Zubcevik was involved in innovation in both the clinical and research arenas, serving as a Principal Investigator to clinical trials and Clinical co-Director. She was also an Executive Director at LIV NGO, a non-profit organization. “Nevena’s broad expertise and proven track record as a physician and her experience in global clinical development will be invaluable to Endonovo as we continue to advance our pipeline of products and treatments,” Endonovo CEO Alan Collier stated. “Nevena has a number of publications and has been a speaker and presenter at medical conferences that date back to 2000. Her experience, contacts and knowledge of our market is unprecedented and it is with great pleasure that I welcome Nevena as our chief medical officer to the Endonovo family.” “It is a privilege to join the Endonovo team,” commented Dr. Zubcevik. “I look forward to advancing the PEMF assets which improve the quality of life for postoperative patients. Over the last few months I’ve witnessed firsthand Endonovo’s incredible growth trajectory and the market’s validation of the company’s FDA cleared SofPulse product and am looking forward to growing the clinical applications of this fantastic technology as we combat the opioid epidemic.” About Endonovo Therapeutics Endonovo Therapeutics, Inc. is a commercial-stage developer of non-invasive wearable Electroceuticals™ therapeutic devices. The Company's current portfolio of commercial a...